Kevin Patrick Becker M.D., Ph.D.

Assistant Professor of Medicine (Medical Oncology) and of Neurology

Specialties & Subspecialties

Cancer Center, Yale: Brain Tumor Center

Neurology: Brain Tumors and Neuro-Oncology

Education & Training

  • B.S., SUNY at Stonybrook (1995)
  • M.D., University of South Carolina College of Medicine (2005)
  • Residency, Yale-New Haven Hospital , Neurology (2006 - 2009)
  • Fellowship, Yale University School of Medicine , Neuro-Oncology (2009 - 2010)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

evaluation, treatment and management of all forms of primary brain tumors; consultative support for the medical oncology community for patients with systemic cancer that involves the central nervous system either directly or indirectly; evaluation, treatment and management of difficult general neurology cases; future establishment of a comprehensive care experience for patients with glioblastoma.


Cancers Treated

Brain


Board Certifications

  • Neurology, Board Certified (2010)

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients with Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)
Brain and Nervous SystemA Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination with Ipilimumab Across Different Lines of Glioblastoma
Brain and Nervous SystemTAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride with Hypofractionated Re-Irradiation Therapy in Treating Patients with Recurrent Glioblastoma Multiforme (GBM)
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies

Edit Profile